BR9808016A - Composições e métodos para redução da hipertensão ocular - Google Patents

Composições e métodos para redução da hipertensão ocular

Info

Publication number
BR9808016A
BR9808016A BR9808016-4A BR9808016A BR9808016A BR 9808016 A BR9808016 A BR 9808016A BR 9808016 A BR9808016 A BR 9808016A BR 9808016 A BR9808016 A BR 9808016A
Authority
BR
Brazil
Prior art keywords
compositions
prostaglandin
methods
ocular hypertension
reducing
Prior art date
Application number
BR9808016-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Kenneth Warren Reed
Shau-Fong Yen
Mary Sou
Regina Flinn Peacock
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38729083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9808016(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Priority to BRPI9816218A priority Critical patent/BRPI9816218B1/pt
Publication of BR9808016A publication Critical patent/BR9808016A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
BR9808016-4A 1997-03-17 1998-03-13 Composições e métodos para redução da hipertensão ocular BR9808016A (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BRPI9816218A BRPI9816218B1 (pt) 1997-03-17 1998-03-13 "composições para redução da hipertensão ocular, e seu uso na preparação de composições oftálmicas"

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81922197A 1997-03-17 1997-03-17
PCT/EP1998/001483 WO1998041208A1 (en) 1997-03-17 1998-03-13 Compositions and methods for reducing ocular hypertension

Publications (1)

Publication Number Publication Date
BR9808016A true BR9808016A (pt) 2000-03-08

Family

ID=38729083

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI9816218A BRPI9816218B1 (pt) 1997-03-17 1998-03-13 "composições para redução da hipertensão ocular, e seu uso na preparação de composições oftálmicas"
BR9808016-4A BR9808016A (pt) 1997-03-17 1998-03-13 Composições e métodos para redução da hipertensão ocular

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI9816218A BRPI9816218B1 (pt) 1997-03-17 1998-03-13 "composições para redução da hipertensão ocular, e seu uso na preparação de composições oftálmicas"

Country Status (32)

Country Link
EP (1) EP0969846B2 (enExample)
JP (2) JP4920124B2 (enExample)
KR (1) KR100555818B1 (enExample)
CN (1) CN1236775C (enExample)
AR (2) AR002194A1 (enExample)
AT (1) ATE257385T1 (enExample)
AU (1) AU738781B2 (enExample)
BR (2) BRPI9816218B1 (enExample)
CA (1) CA2280089C (enExample)
CL (1) CL2009001870A1 (enExample)
CO (1) CO4940427A1 (enExample)
CY (1) CY2526B1 (enExample)
CZ (1) CZ299833B6 (enExample)
DE (1) DE69820997T3 (enExample)
DK (1) DK0969846T4 (enExample)
EE (1) EE04091B1 (enExample)
ES (1) ES2214706T5 (enExample)
HU (1) HU228896B1 (enExample)
ID (1) ID22389A (enExample)
IL (1) IL131041A0 (enExample)
MY (1) MY122237A (enExample)
NO (1) NO327713B1 (enExample)
NZ (1) NZ337322A (enExample)
PE (1) PE61899A1 (enExample)
PL (1) PL197509B1 (enExample)
PT (1) PT969846E (enExample)
RU (1) RU2197970C2 (enExample)
SI (1) SI0969846T2 (enExample)
TW (1) TW527187B (enExample)
UA (1) UA63938C2 (enExample)
WO (1) WO1998041208A1 (enExample)
ZA (1) ZA982188B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US6187818B1 (en) * 1998-06-17 2001-02-13 Pharmacia & Upjohn Company Prostaglandins formulation and process
JP4880808B2 (ja) * 1999-11-15 2012-02-22 久光製薬株式会社 人工涙液型点眼剤組成物
TWI290470B (en) * 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
DK1321144T3 (da) * 2000-09-13 2011-03-07 Santen Pharmaceutical Co Ltd Øjendråber
WO2002045748A1 (en) * 2000-12-05 2002-06-13 Sankyo Company, Limited Ocular tension-lowering compositions for topical administration
US20020198209A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
RU2266572C1 (ru) * 2004-03-17 2005-12-20 Российский государственный медицинский университет Способ моделирования злокачественной артериальной гипертонии
ES2331890T3 (es) * 2004-03-18 2010-01-19 R-Tech Ueno, Ltd. Composicion acuosa que comprende un derivado de tiazol.
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) * 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
DE202005005094U1 (de) * 2005-03-31 2005-07-28 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Ophthalmische Zusammensetzung
JP5252787B2 (ja) * 2005-08-02 2013-07-31 参天製薬株式会社 熱的に不安定な薬物の分解抑制方法
EP1916002B1 (en) * 2005-08-02 2014-03-05 Santen Pharmaceutical Co., Ltd. Method for prevention of degradation of thermally unstable substance
JP2007099647A (ja) * 2005-09-30 2007-04-19 Kobayashi Pharmaceut Co Ltd 粘膜適用組成物
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
JPWO2007105691A1 (ja) * 2006-03-13 2009-07-30 株式会社アールテック・ウエノ 水性組成物
JP5275214B2 (ja) * 2006-03-17 2013-08-28 ジョンソン・アンド・ジョンソン・ビジョン・ケア・インコーポレイテッド 酸化に不安定な成分を含む眼科用安定組成物
AU2007313684A1 (en) * 2006-10-31 2008-05-08 Alcon Research, Ltd. PAI-1 binding modulators for the treatment of ocular disorders
JPWO2008096804A1 (ja) * 2007-02-07 2010-05-27 テイカ製薬株式会社 ラタノプロスト含有点眼剤
JP2009073788A (ja) * 2007-09-21 2009-04-09 Teika Seiyaku Kk イソプロピルウノプロストン含有眼用組成物
CN101820917B (zh) * 2007-10-08 2013-01-02 佛维雅制药股份有限公司 水性眼科配制剂
AU2009225931B9 (en) * 2008-03-17 2014-04-03 Novartis Ag Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
RU2402316C2 (ru) * 2009-01-11 2010-10-27 Пшеничников Виталий Георгиевич Фармацевтическая антиглаукомная композиция
US8952051B2 (en) * 2009-11-05 2015-02-10 Allergan, Inc. Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
JP2014510709A (ja) * 2011-04-12 2014-05-01 株式会社アールテック・ウエノ 眼科用水性組成物
US20130029919A1 (en) 2011-07-26 2013-01-31 Allergan, Inc. Two part formulation system for opthalmic delivery
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
HUE057140T2 (hu) 2011-12-07 2022-04-28 Allergan Inc Hatásos lipidszállítás humán könny-filmhez sóérzékeny emulziórendszer alkalmazásával
RU2697844C9 (ru) 2014-11-25 2019-10-01 Аллерган, Инк. Стабилизированные композиции для офтальмологического применения, содержащие омега-3-кислоты
AU2019343188A1 (en) * 2018-09-21 2021-05-20 Aufbau Medical Innovations Limited Compositions and methods for glaucoma
BR112021020425A2 (pt) 2019-04-12 2021-12-14 Ecolab Usa Inc Composições de limpeza multiuso concentrada e pronta para uso, e, métodos para limpar uma superfície e de fabricação da composição de limpeza multiuso

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0458587B1 (en) * 1990-05-22 1993-07-14 R-Tech Ueno Ltd. Synergistic combination for ophthalmic use
IE920397A1 (en) * 1991-02-07 1992-08-12 Allergan Inc 2-decarboxyl-2-hydroxyalkyl-5-trans prostaglandin f¹derivatives
US5767154A (en) * 1991-02-07 1998-06-16 Allergan 5-trans-prostaglandins of the F series and their use as ocular hypotensives
JP2742333B2 (ja) * 1994-05-06 1998-04-22 アルコン ラボラトリーズ，インコーポレイテッド 眼科用組成物におけるビタミンｅトコフェリル誘導体の使用
US5631287A (en) † 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5558876A (en) * 1995-03-29 1996-09-24 Alcon Laboratories, Inc. Topical ophthalmic acidic drug formulations
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.

Also Published As

Publication number Publication date
CL2009001870A1 (es) 2010-01-22
DE69820997T3 (de) 2011-10-06
RU2197970C2 (ru) 2003-02-10
NZ337322A (en) 2001-05-25
PE61899A1 (es) 1999-06-30
SI0969846T1 (en) 2004-06-30
CY2526B1 (en) 2006-02-08
SI0969846T2 (sl) 2010-12-31
EE9900410A (et) 2000-04-17
JP2010043110A (ja) 2010-02-25
ID22389A (id) 1999-10-07
EP0969846B2 (en) 2010-08-25
KR100555818B1 (ko) 2006-03-03
ATE257385T1 (de) 2004-01-15
NO327713B1 (no) 2009-09-14
KR20000076330A (ko) 2000-12-26
CO4940427A1 (es) 2000-07-24
WO1998041208A1 (en) 1998-09-24
DK0969846T4 (da) 2010-12-20
JP4920124B2 (ja) 2012-04-18
PL197509B1 (pl) 2008-04-30
CA2280089C (en) 2009-03-03
HU228896B1 (en) 2013-06-28
HK1026841A1 (en) 2000-12-29
BRPI9816218B1 (pt) 2016-04-12
JP2001515502A (ja) 2001-09-18
DE69820997T2 (de) 2004-12-09
TW527187B (en) 2003-04-11
DE69820997D1 (de) 2004-02-12
HUP0002194A2 (hu) 2000-12-28
ES2214706T5 (es) 2011-02-02
HUP0002194A3 (en) 2012-08-28
EP0969846A1 (en) 2000-01-12
CZ299833B6 (cs) 2008-12-10
AU738781B2 (en) 2001-09-27
ZA982188B (en) 1998-09-17
AU7035398A (en) 1998-10-12
MY122237A (en) 2006-04-29
EP0969846B1 (en) 2004-01-07
NO994481D0 (no) 1999-09-16
AR002194A1 (es) 1998-01-07
CN1249687A (zh) 2000-04-05
IL131041A0 (en) 2001-01-28
ES2214706T3 (es) 2004-09-16
NO994481L (no) 1999-09-16
PL335168A1 (en) 2000-04-10
PT969846E (pt) 2004-05-31
CN1236775C (zh) 2006-01-18
AR011192A1 (es) 2000-08-02
CA2280089A1 (en) 1998-09-24
UA63938C2 (uk) 2004-02-16
DK0969846T3 (da) 2004-04-13
EE04091B1 (et) 2003-08-15
CZ325799A3 (cs) 2000-01-12

Similar Documents

Publication Publication Date Title
BR9808016A (pt) Composições e métodos para redução da hipertensão ocular
MX9405006A (es) Solucion oftalmica para lagrimas artificiales.
IT1277707B1 (it) Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
ES2178263T3 (es) Composiciones oftarmologicas que contienen un glicosido cationico y unagente terapeutico anionico.
MX9702349A (es) Usos de derivado de 9-deoxi prostaglandina para tratar glaucoma.
KR101820184B1 (ko) 방부제가 없는 비마토프로스트 및 티몰롤 용액
NO975962L (no) Legemiddelpreparat som omfatter albumin som aktiv bestanddel
WO2002049615A3 (en) Artificial tear composition containing a combination of three demulcents
JP5078254B2 (ja) 眼科用組成物
ES2183148T3 (es) Composiciones oftalmicas que contienen un inhibidor de anhidrasa carbonica y de la goma de xantano.
WO2002049611A3 (en) Ophthalmic lubricating solution adapted for use in lasik surgery
AU609807B2 (en) A composition for the topical treatment of glaucoma or ocular hypertension
JP3175742B1 (ja) コンタクトレンズ用眼科用組成物
ITRM20010438A1 (it) Preparato oftalmico a base di n-acetilcisteina per il trattamento della sindrome dell'occhio secco.
BR0209601A (pt) Método para o tratamento da hipertensão ocular e do glaucoma
PT1021184E (pt) Utilizacao de flunarizina para o tratamento topico da hipertensao ocular
MXPA04000980A (es) Tratamiento de hipertension ocular y glaucoma.
Serle et al. Effect of pilocarpine 4% in combination with latanoprost 0.005% or 8-iso prostaglandin E2 0.1% on intraocular pressure in laser-induced glaucomatous monkey eyes
ES2106852T3 (es) Composicion oftalmica que contiene hemihidrato de timolol.
ATE227135T1 (de) Miotische wirkstoffe und hypertonische wirkstoffe enthaltende ophthalmische zusammensetzungen
JP2011084575A (ja) 点眼液
JP4736540B2 (ja) 眼科用粘稠化剤
ECSP982443A (es) Composiciones y metodos para reducir la hipertension ocular
JP5041761B2 (ja) 眼粘膜適用製剤
JP2002104971A (ja) 眼科用組成物

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AO DISPOSTO NOS ARTIGOS 8O, 11 E 25 DA LPI

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DA INT.CL: A61K 31/557, A61K 9/00, AO1B 1/00

Ipc: A61K 31/557 (2010.01), A61K 9/00 (2010.01), A61P 2